127 related articles for article (PubMed ID: 16404230)
1. The management of differentiated thyroid cancer using 123I for imaging to assess the need for 131I therapy.
Ali N; Sebastian C; Foley RR; Murray I; Canizales AL; Jenkins PJ; Drake WM; Plowman PN; Besser GM; Chew SL; Grossman AB; Monson JP; Britton KE
Nucl Med Commun; 2006 Feb; 27(2):165-9. PubMed ID: 16404230
[TBL] [Abstract][Full Text] [Related]
2. The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning.
Siddiqi A; Foley RR; Britton KE; Sibtain A; Plowman PN; Grossman AB; Monson JP; Besser GM
Clin Endocrinol (Oxf); 2001 Oct; 55(4):515-21. PubMed ID: 11678835
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
[TBL] [Abstract][Full Text] [Related]
4. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I.
Hilditch TE; Dempsey MF; Bolster AA; McMenemin RM; Reed NS
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):783-8. PubMed ID: 12029552
[TBL] [Abstract][Full Text] [Related]
5. Timing of post 131I ablation diagnostic whole body scan in differentiated thyroid cancer patients. Less than four months post ablation may be too early.
Winter M; Winter J; Heinzel A; Behrendt FF; Krohn T; Mottaghy FM; Verburg FA
Nuklearmedizin; 2015; 54(4):151-7. PubMed ID: 26028188
[TBL] [Abstract][Full Text] [Related]
6. 123I isotope as a diagnostic agent in the follow-up of patients with differentiated thyroid cancer: comparison with post 131I therapy whole body scanning.
Alzahrani AS; Bakheet S; Al Mandil M; Al-Hajjaj A; Almahfouz A; Al Haj A
J Clin Endocrinol Metab; 2001 Nov; 86(11):5294-300. PubMed ID: 11701695
[TBL] [Abstract][Full Text] [Related]
7. Iodine-123 as a diagnostic imaging agent in differentiated thyroid carcinoma: a comparison with iodine-131 post-treatment scanning and serum thyroglobulin measurement.
Urhan M; Dadparvar S; Mavi A; Houseni M; Chamroonrat W; Alavi A; Mandel SJ
Eur J Nucl Med Mol Imaging; 2007 Jul; 34(7):1012-7. PubMed ID: 17256140
[TBL] [Abstract][Full Text] [Related]
8. Neck and whole-body scanning with 5-mCi dose of (123)I as diagnostic tracer in patients with well-differentiated thyroid cancer.
Gulzar Z; Jana S; Young I; Bukberg P; Yen V; Naddaf S; Abdel-Dayem HM
Endocr Pract; 2001; 7(4):244-9. PubMed ID: 11497474
[TBL] [Abstract][Full Text] [Related]
9. Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I whole-body scanning results?
Ma C; Xie J; Kuang A
J Nucl Med; 2005 Jul; 46(7):1164-70. PubMed ID: 16000286
[TBL] [Abstract][Full Text] [Related]
10. 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning.
Dam HQ; Kim SM; Lin HC; Intenzo CM
Radiology; 2004 Aug; 232(2):527-33. PubMed ID: 15286323
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of the differences between diagnostic 123I and post-therapy 131I scans.
Cohen JB; Kalinyak JE; McDougall IR
Nucl Med Commun; 2004 Feb; 25(2):129-34. PubMed ID: 15154700
[TBL] [Abstract][Full Text] [Related]
12. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma.
Leger FA; Izembart M; Dagousset F; Barritault L; Baillet G; Chevalier A; Clerc J
Eur J Nucl Med; 1998 Mar; 25(3):242-6. PubMed ID: 9580856
[TBL] [Abstract][Full Text] [Related]
13. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates.
Karam M; Gianoukakis A; Feustel PJ; Cheema A; Postal ES; Cooper JA
Nucl Med Commun; 2003 May; 24(5):489-95. PubMed ID: 12717064
[TBL] [Abstract][Full Text] [Related]
14. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
Cholewinski SP; Yoo KS; Klieger PS; O'Mara RE
J Nucl Med; 2000 Jul; 41(7):1198-202. PubMed ID: 10914909
[TBL] [Abstract][Full Text] [Related]
15. Which thyroid cancer patients need periodic stimulation tests?
Zanotti-Fregonara P; Khoury A; Duron F; Keller I; Christin-Maître S; Kiffel T; Toubert ME; Devaux JY; Hindié E
Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):541-6. PubMed ID: 17106700
[TBL] [Abstract][Full Text] [Related]
16. Nuclear imaging in the management of thyroid carcinoma.
Cavalieri RR
Thyroid; 1996 Oct; 6(5):485-92. PubMed ID: 8936676
[TBL] [Abstract][Full Text] [Related]
17. Detection of thyroid remnant/metastasis without stunning: an ongoing dilemma.
Park HM; Park YH; Zhou XH
Thyroid; 1997 Apr; 7(2):277-80. PubMed ID: 9133700
[TBL] [Abstract][Full Text] [Related]
18. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131.
Park HM; Perkins OW; Edmondson JW; Schnute RB; Manatunga A
Thyroid; 1994; 4(1):49-54. PubMed ID: 8054861
[TBL] [Abstract][Full Text] [Related]
19. Influence of 131I diagnostic dose on subsequent ablation in patients with differentiated thyroid carcinoma: discrepancy between the presence of visually apparent stunning and the impairment of successful ablation.
Hu YH; Wang PW; Wang ST; Lee CH; Chen HY; Chou FF; Huang YE; Huang HH
Nucl Med Commun; 2004 Aug; 25(8):793-7. PubMed ID: 15266173
[TBL] [Abstract][Full Text] [Related]
20. The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery.
Rubello D; Mazzarotto R; Casara D
Eur J Nucl Med; 2000 Apr; 27(4):431-40. PubMed ID: 10805117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
